Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MindBio Therapeutics Corp. C.MBIO

Healthcare Biotechnology
MindBio Therapeutics Corp is a pioneering clinical stage biotechnology company that specializes in developing psychedelic microdosing treatments for mental health conditions. MindBio has obtained government and regulatory approvals for at-home LSD microdosing in clinical trials, making it the only organization in the world to do so.

Recent & Breaking News (CSE:MBIO)

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

Accesswire 6 days ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

Business Wire May 14, 2024

MindBio Therapeutics Scientists Present Landmark Women's Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month

Accesswire May 2, 2024

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

Accesswire May 1, 2024

MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials

Accesswire April 30, 2024

MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry

Accesswire April 23, 2024

Lender Requests to Convert Loan to MindBio Shares

Accesswire April 16, 2024

Psychedelic stock begins take-home LSD microdosing clinical trial

Jonathon Brown March 20, 2024

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder

Accesswire March 20, 2024

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Accesswire March 4, 2024

Psychedelic stock clears hurdle to treating depression with LSD

Trevor Abes  February 26, 2024

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial

Accesswire February 26, 2024

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial

Accesswire February 14, 2024

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients

Accesswire January 30, 2024

MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials

Accesswire December 20, 2023

MindBio Therapeutics Team Members Honoured with Industry Leading Awards

Accesswire November 21, 2023

MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients

Accesswire October 31, 2023

MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients

Accesswire October 28, 2023

Mindbio Therapeutics Nominated for Company of the Year in Industry Awards

Accesswire October 26, 2023

MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001

Accesswire October 24, 2023